

UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001

February 16, 2012

George Segall, M.D. SNM President 1850 Samuel Morse Drive Reston, Virginia 20190-5316

Dear Dr. Segall:

I am writing in response to your letter dated February 6, 2012, regarding the training and experience requirements for the medical use of Radium-223 chloride. I appreciate SNM sharing their view that the diplomates of American Board of Nuclear Medicine have the core knowledge necessary to safely administer therapeutic doses of all unsealed radioactive sources regardless of their mode of decay. NRC staff will consider this information when licensing new therapies.

Sincerely.

Christian E. Einberg

Chief, Radioactive Materials

Safety Branch

Division of Materials Safety and

State Agreements

Office of Federal and State Materials and Environmental Management

Programs